Regulation of arterial remodeling and angiogenesis by urokinase- type plasminogen activator

Canadian Journal of Physiology and Pharmacology

Volumn 87, Issue 4, 2009, Pages 231-251

  Tkachuk, Vsevolod A ^a,b   Plekhanova, Olga S ^b   Parfyonova, Yelena V ^b  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Arterial remodeling; Migration; Proliferation; Restenosis; Urokinase

Indexed keywords

CASPASE; CYTOKINE; GROWTH FACTOR; PROTEIN; SMALL INTERFERING RNA; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ANGIOGENESIS; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; BLOOD VESSEL WALL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DRUG TARGETING; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBRINOLYSIS; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULITIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ARTERIES; CELL MOVEMENT; CELL PROLIFERATION; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; HUMANS; INFLAMMATION MEDIATORS; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULITIS;

EID: 65249116364     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y08-113     Document Type: Review

References (235)

1. Agrotis, A., and Bobik, A. 1996. Vascular remodelling and molecular biology: new concepts and therapeutic possibilities. Clin. Exp. Pharmacol. Physiol. 23: 363-368. doi:10.1111/j.1440-1681.1996.tb02742.x. PMID:8713672.
2. Agrotis, A., Kalinina, N., and Bobik, A. 2005. Transforming growth factor-beta, cell signaling and cardiovascular disorders. Curr. Vasc. Pharmacol. 3(1): 55-61. doi:10.2174/1570161052773951. PMID:15638782.
3. Alexander, R.W. 1995. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response, a new perspective. Hypertension, 25: 155-161. PMID: 7843763.
4. Andreasen, P.A., Kjoller, L., Christensen, L., and Duffy, M.J. 1997. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72: 1-22. doi:10.1002/(SICI) 1097-0215(19970703)72:1〈1:: AID-IJC1〉3.0.CO;2-Z. PMID:9212216.
5. Anichini, E., Fibbi, G., Pucci, M., Caldini, R., Chevanne, M., and Del Rosso, M. 1994. Production of second messengers following chemotactic and mitogenic urokinase- receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor. Exp. Cell Res. 213: 438-448. doi:10.1006/excr.1994.1221. PMID:8050501.
6. Appella, E., Robinson, E.A., Ullrich, S.J., Stoppelli, M.P., Corti, A., Cassani, G., and Blasi, F. 1987. The receptor-binding sequence of urokinase: a biological function for the growth-factor module of proteases. J. Biol. Chem. 262: 4437-4440. PMID:3031025.
7. Argraves, K.M., Battey, F.D., MacCalman, C.D., McCrae, K.R., Gafvels, M., Kozarsky, K.F., et al. 1995. The very low density lipoprotein receptor mediates the cellular catabolism of lipopro- tein lipase and urokinase-plasminogen activator inhibitor type I complexes. J. Biol. Chem. 270: 26550-26557. doi:10.1074/jbc. 270.31.18558. PMID:7592875.
8. Arras, M., Ito, W.D., Scholz, D., Winkler, B., Schaper, J., and Schaper, W. 1998. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J. Clin. Invest. 101: 40-50. doi:10.1172/JCI119877. PMID:9421464.
9. Azevedo, L.C., Pedro, M.A., Souza, L.C., de Souza, H.P., Janis- zewski, M., da Luz, P.L., and Laurindo, F.R. 2000. Oxidative stress as a signaling mechanism of the vascular response to injury: the redox hypothesis of restenosis. Cardiovasc. Res. 47: 436-445. doi:10.1016/S0008-6363(00) 00091-2. PMID: 10963717.
10. Berk, B.C. 1999. Redox signals that regulate the vascular response to injury. Thromb. Haemost. 82: 810-817. PMID:10605787.
11. Berk, B.C. 2001. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol. Rev. 81: 999-1030. PMID:11427690.
12. Berk, B.C. 2007. Novel approaches to treat oxidative stress and cardiovascular diseases. Trans. Am. Clin. Climatol. Assoc. 118: 209-214. PMID:18528504.
13. Besser, D., Presta, M., and Nagamine, Y. 1995. Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. Cell Growth Differ. 6: 1009-1017. PMID:8547215.
14. Bhoday, J., de Silva, S., and Xu, Q. 2006. The molecular mechanisms of vascular restenosis: which genes are crucial? Curr. Vasc. Pharmacol. 4: 269-275. doi:10.2174/157016106777698397. PMID:16842144.
15. Binder, B.R., Mihaly, J., and Prager, G.W. 2007. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb. Haemost. 97(3): 336-342. PMID:17334498.
16. Blasi, F. 1999. The urokinase receptor: a cell surface, regulated chemokine. APMIS, 107: 96-101. PMID:10190285.
17. Bobik, A., and Tkachuk, V. 2003. Metalloproteinases and plasmino- gen activators in vessel remodeling. Curr. Hypertens. Rep. 5(6): 466-472. doi:10.1007/s11906-003-0054-5. PMID:14594565.
18. Bohuslav, J., Horejsi, V., Hansmann, C., Stockl, J., Weidle, U.H., Majdic, O., et al. 1995. Urokinase plasminogen activator receptor, beta 2-integrins, and Src- kinases within a single receptor complex of human monocytes. J. Exp. Med. 181: 1381-1390. doi:10.1084/jem.181.4.1381. PMID:7535337.
19. Bose, D., Leineweber, K., Konorza, T., Zahn, A., Brocker- Preuss, M., Mann, K., et al. 2007. Release of TNF-alpha during stent implantation into saphenous vein aortocoronary bypass grafts and its relation to plaque extrusion and restenosis. Am. J. Physiol. Heart Circ. Physiol. 292: H2295-H2299. doi:10.1152/ ajpheart.01116.2006. PMID:17208993.
20. Boyle, J.J. 2005. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr. Vasc. Pharmacol. 3: 63-68. doi:10.2174/1570161052773861. PMID: 15638783.
21. Braat, E.A., Levi, M., Bos, R., Haverkate, F., Lassen, M.R., de Maat, M.P., and Rijken, D.C. 1999. Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects. J. Lab. Clin. Med. 134: 161-167. doi:10.1016/S0022- 2143(99)90121-X. PMID:10444030.
22. Brack, M.J., More, R.S., Pringle, S., and Gershlick, A.H. 1994. Absence of a prothrombotic state in restenotic patients? Coron. Artery Dis. 5: 501-506. PMID:7952409.
23. Busso, N., Masur, S.K., Lazega, D., Waxman, S., and Ossowski, L. 1994. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. 126 : 259-270. doi:10.1083/jcb.126. 1.259. PMID:7517943.
24. Cao, D., Mizukami, I.F., Garni-Wagner, B.A., Kindzelskii, A.L., Todd, R.F., III, Boxer, L.A., and Petty, H.R. 1995. Human urokinase- type plasminogen activator primes neutrophils for super- oxide anion release: possible roles of complement receptor type 3 and calcium. J. Immunol. 154: 1817-1829. PMID:7836767.
25. Carmeliet, P., and Collen, D. 1996. Genetic analysis of the plasminogen and coagulation system in mice. Haemostasis, 26(Suppl 4): 132-153. PMID:8979118.
26. Carmeliet, P., and Collen, D. 1997. Molecular analysis of blood vessel formation and disease. Am. J. Physiol. 273(5 Pt 2): H2091-H2104. PMID:9374741.
27. Carmeliet, P., Moons, L., Dewerchin, M., Mackman, N., Luther, T., Breier, G., et al. 1997a. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann. N. Y. Acad. Sci. 811: 191-206. doi:10.1111/j.1749-6632.1997.tb52002.x. PMID:9186598.
28. Carmeliet, P., Moons, L., Herbert, J.M., Crawley, J., Lupu, F., Lij- nen, R., and Collen, D. 1997b. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ. Res. 81: 829-839. PMID:9351457.
29. Carmeliet, P., Moons, L., Lijnen, R., Baes, M., Lemaitre, V., Tipping, P., et al. 1997c. Urokinase- generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genet. 17: 439-444. doi:10.1038/ng1297-439. PMID:9398846.
30. Carmeliet, P., Moons, L., Ploplis, V., Plow, E., and Collen, D. 1997d. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J. Clin. Invest. 99: 200-208. doi:10.1172/ JCI119148. PMID:9005988.
31. Carmeliet, P., Moons, L., Dewerchin, M., Rosenberg, S., Herbert, J.M., Lupu, F., and Collen, D. 1998. Receptor-independent role of urokinase- type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J. Cell Biol. 140: 233-245. doi:10.1083/jcb.140. 1.233. PMID:9425170.
32. Chandrasekar, B., and Tanguay, J.F. 2000. Platelets and restenosis. J. Am. Coll. Cardiol. 35: 555-562. doi:10.1016/S0735-1097(99) 00596-3. PMID:10716455.
33. Chang, A.W., Kuo, A., Barnathan, E.S., and Okada, S.S. 1998. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase. Arterioscler. Thromb. Vasc. Biol. 18: 1855-1860. PMID:9848876.
34. Cho, A., and Reidy, M.A. 2002. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ. Res. 91: 845-851. doi:10. 1161/01.RES.0000040420. 17366.2E. PMID:12411400.
35. Christ, G., Kostner, K., Zehetgruber, M., Binder, B.R., Gulba, D., and Huber, K. 1999. Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? J. Thromb. Throm- bolysis, 7: 277-285. doi:10.1023/A:1008983110941. PMID: 10375389.
36. Cipollone, F., Marini, M., Fazia, M., Pini, B., Iezzi, A., Reale, M., et al. 2001. Elevated circulating levels of monocyte chemoat- tractant protein-1 in patients with restenosis after coronary an- gioplasty. Arterioscler. Thromb. Vasc. Biol. 21: 327-334. PMID:11231910.
37. Clowes, A.W., Clowes, M.M., Au, Y.P., Reidy, M.A., and Belin, D. 1990. Smooth muscle cells express urokinase during mito- genesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ. Res. 67: 61-67. PMID:2114227.
38. Clowes, A.W., Clowes, M.M., Kirkman, T.R., Jackson, C.L., Au, Y.P., and Kenagy, R. 1992. Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery. Circ. Res. 70: 1128-1136. PMID:1374298.
39. Colombo, E.S., Menicucci, G., McGuire, P.G., and Das, A. 2007. Hepatocyte growth factor/scatter factor promotes retinal angio- genesis through increased urokinase expression. Invest. Ophthalmol. Vis. Sci. 48(4): 1793-1800. doi:10.1167/iovs.06-0923. PMID:17389513.
40. Conese, M., Olson, D., and Blasi, F. 1994. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor. J. Biol. Chem. 269: 17886-17892. PMID:8027043.
41. Conese, M., Nykjaer, A., Petersen, C.M., Cremona, O., Pardi, R., Andreasen, P.A., et al. 1995. alpha-2 Macroglobulin receptor/ Ldl receptor-related protein (Lrp)-dependent internalization of the urokinase receptor. J. Cell Biol. 131: 1609-1622. doi:10. 1083/jcb.131.6.1609. PMID:8522616.
42. Cozen, A.E., Moriwaki, H., Kremen, M., DeYoung, M.B., Dichek, H.L., Slezicki, K.I., et al. 2004. Macrophage- targeted overex- pression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation, 109: 2129-2135. doi:10.1161/01.CIR.0000127369.24127. 03. PMID: 15096455.
43. Cubellis, M.V., Nolli, M.L., Cassani, G., and Blasi, F. 1986. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J. Biol. Chem. 261: 15819-15822. PMID:3023326.
44. Davis, C., Fischer, J., Ley, K., and Sarembock, I.J. 2003. The role of inflammation in vascular injury and repair. J. Thromb. Hae- most. 1: 1699-1709. doi:10.1046/j.1538-7836.2003.00292.x. PMID:12911580.
45. De Leon, H., Ollerenshaw, J.D., Griendling, K.K., and Wilcox, J.N. 2001. Adventitial cells do not contribute to neointimal mass after balloon angioplasty of the rat common carotid artery. Circulation, 104: 1591-1593. PMID:11581133.
46. De Petro, G., Copeta, A., and Barlati, S. 1994. Urokinase- type and tissue-type plasminogen activators as growth factors of human fibroblasts. Exp. Cell Res. 213: 286-294. doi:10.1006/excr. 1994.1200. PMID:8020601.
47. Deindl, E., Ziegelhoffer, T., Kanse, S.M., Fernandez, B., Neubauer, E., Carmeliet, P., et al. 2003. Receptor-independent role of the urokinase -type plasminogen activator during arteriogenesis. FASEB J. 17: 1174-1176. PMID:12692088.
48. Del Rosso, M., Fibbi, G., Pucci, M., Margheri, F., and Serrati, S. 2008. The plasminogen activation system in inflammation. Front. Biosci. 13: 4667-4686. doi:10.2741/3032. PMID:18508538.
49. Deng, G., Curriden, S.A., Wang, S., Rosenberg, S., and Loskutoff, D.J. 1996. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134: 1563-1571. doi:10.1083/jcb.134. 6.1563. PMID:8830783.
50. Di Mario, C., Gil, R., Camenzind, E., Ozaki, Y., von Birgelen, C., Umans, V., et al. 1995. Quantitative assessment with intracoron- ary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am. J. Cardiol. 75: 772-777. doi:10.1016/S0002-9149(99)80409-3. PMID:7717277.
51. Ding, H., Wang, R., Marcel, R., and Fisher, D.Z. 2001. Adeno- virus-mediated expression of a truncated PDGFbeta receptor inhibits thrombosis and neointima formation in an avian arterial injury model. Thromb. Haemost. 86: 914-922. PMID: 11583327.
52. Duffy, M.J., Maguire, T.M., McDermott, E.W., and O'Higgins, N. 1999. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J. Surg. Oncol. 71: 130-135. doi:10.1002/(SICI)1096-9098(199906) 71:2〈130::AID-JSO14〉3.0. CO;2-9. PMID:10389872.
53. Dumler, I., Petri, T., and Schleuning, W.D. 1993. Interaction of urokinase -type plasminogen activator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett. 322: 37-40. doi:10.1016/0014- 5793(93)81106-A. PMID:8387028.
54. Dumler, I., Weis, A., Mayboroda, O.A., Maasch, C., Jerke, U., Hal- ler, H., and Gulba, D.C. 1998. The Jak/ Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J. Biol. Chem. 273: 315-321. doi:10.1074/jbc.273.1.315. PMID:9417082.
55. Dumler, I., Kopmann, A., Weis, A., Mayboroda, O.A., Wagner, K., Gulba, D.C., and Haller, H. 1999a. Urokinase activates the Jak/ Stat signal transduction pathway in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19: 290-297. PMID:9974409.
56. Dumler, I., Stepanova, V., Jerke, U., Mayboroda, O.A., Vogel, F., Bouvet, P., et al. 1999b. Urokinase-induced mitogenesis is mediated by casein kinase 2 and nucleolin. Curr. Biol. 9:1468-1476. doi:10.1016/S0960-9822(00)80116- 5. PMID: 10607589.
57. Ellis, A., and Triggle, C.R. 2003. Endothelium- derived reactive oxygen species: their relationship to endothelium- dependent hyperpolarization and vascular tone. Can. J. Physiol. Pharmacol. 81(11): 1013-1028. doi:10.1139/y03-106. PMID: 14719036.
58. Estreicher, A., Muhlhauser, J., Carpentier, J.L., Orci, L., and Vas- salli, J.D. 1990. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol. 111: 783-792. doi:10.1083/jcb.111.2.783. PMID:2166055.
59. Fay, W.P., Garg, N., and Sunkar, M. 2007. Vascular functions of the plasminogen activation system. Arterioscler. Thromb. Vasc. Biol. 27: 1231-1237. doi:10.1161/ATVBAHA.107.140046. PMID:17379840.
60. Fazioli, F., Resnati, M., Sidenius, N., Higashimoto, Y., Appella, E., and Blasi, F. 1997. A urokinase- sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 16: 7279-7286. doi:10.1093/emboj/16.24.7279. PMID:9405357.
61. Ferrara, N. 2004. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25(4): 581-611. doi:10.1210/er.2003-0027. PMID:15294883.
62. Furlan, F., Galbiati, C., Jorgensen, N.R., Jensen, J.E., Mrak, E., Ru- binacci, A., et al. 2007. Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function. J. Bone Miner. Res. 22: 1387-1396. doi:10.1359/jbmr.070516. PMID:17539736.
63. Gabbiani, G. 2003. The myofibroblast in wound healing and fibro- contractive diseases. J. Pathol. 200: 500-503. doi:10.1002/path. 1427. PMID:12845617.
64. Gabbiani, G., Ryan, G.B., and Majne, G. 1971. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia, 27: 549-550. doi:10.1007/BF02147594. PMID:5132594.
65. Galis, Z.S., Johnson, C., Godin, D., Magid, R., Shipley, J.M., Senior, R.M., and Ivan, E. 2002. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ. Res. 91: 852-859. doi:10.1161/01.RES.0000041036.86977.14. PMID:12411401.
66. Gardsvoll, H., and Ploug, M. 2007. Mapping of the vitronectin- binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J. Biol. Chem. 282:13561-13572. doi:10.1074/jbc.M610184200. PMID:17355965. Garvin, M.R., Labinaz, M., Pels, K., Walley, V.M., Mizgala, H.F., and O'Brien, E.R. 1997. Arterial expression of the plasminogen activator system early after cardiac transplantation. Cardiovasc. Res. 35: 241-249. doi:10.1016/S0008-6363(97)00088-6. PMID: 9349387.
67. Ghosh, S., Brown, R., Jones, J.C., Ellerbroek, S.M., and Stack, M.S. 2000. Urinary-type plasminogen activator (uPA) expression and uPA receptor localization are regulated by alpha 3beta 1 integrin in oral keratinocytes. J. Biol. Chem. 275: 23869-23876. doi:10.1074/jbc.M000935200. PMID:10791952.
68. Godar, S., Horejsi, V., Weidle, U.H., Binder, B.R., Hansmann, C., and Stockinger, H. 1999. M6P/IGFII-receptor complexes uroki- nase receptor and plasminogen for activation of transforming growth factor-beta1. Eur. J. Immunol. 29: 1004-1013. doi:10. 1002/(SICI)1521-4141(199903)29:03〈1004::AID- IMMU1004〉3. 0.CO;2-Q. PMID:10092105.
69. Goncharova, E.A., Vorotnikov, A.V., Gracheva, E.O., Wang, C.L., Panettieri, R.A., Jr., Stepanova, V.V., and Tkachuk, V.A. 2002. Activation of p38 MAP-kinase and caldesmon phosphorylation are essential for urokinase-induced human smooth muscle cell migration. Biol. Chem. 383: 115-126. doi:10.1515/BC.2002. 012. PMID:11930938.
70. Goretzki, L., and Mueller, B.M. 1998. Low- density -lipoprotein -receptor-related protein (LRP) interacts with a GTP- binding protein. Biochem. J. 336(Pt 2): 381-386. PMID:9820815.
71. Gotthardt, M., Trommsdorff, M., Nevitt, M.F., Shelton, J., Richardson, J.A., Stockinger, W., et al. 2000. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J. Biol. Chem. 275: 25616-25624. doi:10.1074/jbc.M000955200. PMID: 10827173.
72. Gualandris, A., Lopez, C.T., Giunciuglio, D., Albini, A., Sabini, E., Rusnati, M., et al. 1997. Urokinase- type plasminogen activator overexpression enhances the invasive capacity of endothelial cells. Microvasc. Res. 53: 254-260. doi:10.1006/mvre.1996. 1998. PMID:9211403.
73. Guo, Y., Higazi, A.A., Arakelian, A., Sachais, B.S., Cines, D., Goldfarb, R.H., et al. 2000. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J. 14: 1400-1410. doi:10.1096/fj.14.10.1400. PMID:10877833.
74. Gyetko, M.R., Sitrin, R.G., Fuller, J.A., Todd, R.F., III, Petty, H., and Standiford, T.J. 1995. Function of the urokinase receptor (CD87) in neutrophil chemotaxis. J. Leukoc. Biol. 58: 533-538. PMID:7595054.
75. Gyetko, M.R., Sud, S., Kendall, T., Fuller, J.A., Newstead, M.W., and Standiford, T.J. 2000. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J. Immunol. 165: 1513-1519. PMID:10903758.
76. Hatane, T., Yoshida, E., Kawano, J., Sugiki, M., Onitsuka, T., and Maruyama, M. 1998. Prostaglandin I2 analog enhances the expression of urokinase- type plasminogen activator and wound healing in cultured human fibroblast. Biochim. Biophys. Acta, 1403: 189-198. doi:10.1016/S0167-4889(98)00041-X. PMID: 9630624.
77. He, C.J., Rebibou, J.M., Peraldi, M.N., Meulders, Q., and Rondeau, E. 1991. Growth factor-like effect of urokinase type plasminogen activator in human renal cells. Biochem. Biophys. Res. Commun. 176: 1408-1416. doi:10.1016/0006-291X(91)90443-B. PMID:1645544.
78. Heeneman, S., Sluimer, J.C., and Daemen, M.J. 2007. Angiotensin- converting enzyme and vascular remodeling. Circ. Res. 101(5):441-454. doi:10.1161/CIRCRESAHA.107.148338. PMID: 17761934.
79. Heil, M., Ziegelhoeffer, T., Pipp, F., Kostin, S., Martin, S., Clauss, M., and Schaper, W. 2002. Blood monocyte concentration is critical for enhancement of collateral artery growth. Am. J. Physiol. Heart Circ. Physiol. 283: H2411-H2419. PMID: 12388258.
80. Herbert, J.M., Lamarche, I., and Carmeliet, P. 1997. Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells. J. Biol. Chem. 272: 23585-23591. doi:10.1074/jbc.272.38. 23585. PMID:9295297.
81. Herz, J., Clouthier, D.E., and Hammer, R.E. 1992. LDL receptor- related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell, 71: 411-421. doi:10.1016/0092-8674(92)90511-A. PMID:1423604.
82. Heymans, S., Luttun, A., Nuyens, D., Theilmeier, G., Creemers, E., Moons, L., et al. 1999. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. 5: 1135-1142. doi:10.1038/13459. PMID:10502816.
83. Hildenbrand, R., Gandhari, M., Stroebel, P., Marx, A., Allgayer, H., and Arens, N. 2008. The urokinase-system- role of cell proliferation and apoptosis. Histol. Histopathol. 23(2): 227-236. PMID:17999379.
84. Hoyer-Hansen, G., Behrendt, N., Ploug, M., Dano, K., and Preiss- ner, K.T. 1997. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 420: 79-85. doi:10.1016/S0014- 5793(97)01491-9. PMID:9450554.
85. Ichinose, A., Fujikawa, K., and Suyama, T. 1986. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem. 261: 3486-3489. PMID:3081506.
86. Jackson, C.L., and Reidy, M.A. 1992. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann. N. Y. Acad. Sci. 667: 141-150. doi:10.1111/j.1749-6632. 1992.tb51606.x. PMID:1339242.
87. Jenkins, G.M., Crow, M.T., Bilato, C., Gluzband, Y., Ryu, W.S., Li, Z., et al. 1998. Increased expression of membrane-type matrix metalloproteinase and preferential localization of matrix me- talloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation, 97: 82-90. PMID:9443435.
88. Kakuta, T., Currier, J.W., Haudenschild, C.C., Ryan, T.J., and Faxon, D.P. 1994. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angio- plasty in the hypercholesterolemic rabbit model. Circulation, 89: 2809-2815. PMID:8205695.
89. Kanamasa, K., Otani, N., Ishida, N., Inoue, Y., Ikeda, A., Morii, H., et al. 2001. Suppression of cell proliferation by tissue plasminogen activator during the early phase after balloon injury minimizes intimal hyperplasia in hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. 37: 155-162. doi:10.1097/00005344- 200102000-00003. PMID:11209998.
90. Kanse, S.M., Kost, C., Wilhelm, O.G., Andreasen, P.A., and Preiss- ner, K.T. 1996. The urokinase receptor is a major vitronectin- binding protein on endothelial cells. Exp. Cell Res. 224: 344-353. doi:10.1006/excr.1996. 0144. PMID:8612711.
91. Kanse, S.M., Benzakour, O., Kanthou, C., Kost, C., Lijnen, H.R., and Preissner, K.T. 1997. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in va- soproliferative disorders. Arterioscler. Thromb. Vasc. Biol. 17: 2848-2854. PMID:9409265. Kantor, B., Ashai, K., Holmes, D.R., Jr., and Schwartz, R.S. 1999. The experimental animal models for assessing treatment of restenosis. Cardiovasc. Radiat. Med. 1: 48-54. doi:10.1016/S1522- 1865(98)00005-5. PMID:11272356.
92. Kenagy, R.D., Vergel, S., Mattsson, E., Bendeck, M., Reidy, M.A., and Clowes, A.W. 1996. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler. Thromb. Vasc. Biol. 16: 1373-1382. PMID:8911276.
93. Keski-Oja, J., Lohi, J., Tuuttila, A., Tryggvason, K., and Vartio, T. 1992. Proteolytic processing of the 72,000-Da type IV col- lagenase by urokinase plasminogen activator. Exp. Cell Res. 202: 471-476. doi:10.1016/0014- 4827(92)90101-D. PMID: 1397099.
94. Khan, M.M., Bradford, H.N., Isordia-Salas, I., Liu, Y., Wu, Y., Espinola, R.G., et al. 2006. High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes. Arterioscler. Thromb. Vasc. Biol. 26: 2260-2266. doi:10.1161/01.ATV. 0000240290.70852.c0. PMID:16902163. Kienast, J., Padro, T., Steins, M., Li, C.X., Schmid, K.W., Ham-mel, D., et al. 1998. Relation of urokinase- type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries. Thromb. Haemost. 79: 579-586. PMID:9531045.
95. Kimura, T., Kaburagi, S., Tamura, T., Yokoi, H., Nakagawa, Y., Yokoi, H., et al. 1997. Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Circulation, 96: 475-483. PMID:9244215.
96. Kiyan, J., Kiyan, R., Haller, H., and Dumler, I. 2005. Urokinase -induced signaling in human vascular smooth muscle cells is mediated by PDGFR- beta. EMBO J. 24: 1787-1797. doi:10. 1038/sj.emboj.7600669. PMID:15889147.
97. Kjoller, L., and Hall, A. 2001. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase- type plasminogen activator receptor binding to vitronectin. J. Cell Biol. 152: 1145-1157. doi:10.1083/jcb.152.6.1145. PMID: 11257116.
98. Konakova, M., Hucho, F., and Schleuning, W.D. 1998. Downstream targets of urokinase -type plasminogen- activator- mediated signal transduction. Eur. J. Biochem. 253: 421-429. doi:10.1046/j.1432-1327.1998.2530421.x. PMID:9654092.
99. Koolwijk, P., van Erck, M.G., de Vree, W.J., Vermeer, M.A., Weich, H.A., Hanemaaijer, R., and van Hinsbergh, V.W. 1996. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothe- lial cells in a fibrin matrix. Role of urokinase activity. J. Cell Biol. 132: 1177-1188. doi:10.1083/jcb.132.6.1177. PMID: 8601593.
100. Korshunov, V.A., Solomatina, M.A., Plekhanova, O.S., Parfyonova, Y.V., Tkachuk, V.A., and Berk, B.C. 2004. Plasminogen activator expression correlates with genetic differences in vascular remodeling. J. Vasc. Res. 41: 481-490. doi:10.1159/000081804. PMID:15528930.
101. Krasnikova, T.L., Parfyonova, Y., Alekseeva, I.A., Arefieva, T.I., Mukhina, S.A., Dobrovolsky, A.B., et al. 1999. Urokinase plas- minogen activator system in humans with stable coronary artery disease. Clin. Exp. Pharmacol. Physiol. 26: 354-357. doi:10.1046/j.1440-1681.1999.03043.x. PMID:10225148.
102. Kubica, J., Kozinski, M., Krzewina- Kowalska, A., Zbikowska- Gotz, M., Dymek, G., Sukiennik, A., et al. 2005. Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. Int. J. Mol. Med. 16: 173-180. PMID:15942695.
103. Kuzuya, M., and Iguchi, A. 2003. Role of matrix metalloprotei- nases in vascular remodeling. J. Atheroscler. Thromb. 10: 275-282. PMID:14718744.
104. Lafont, A., Guzman, L.A., Whitlow, P.L., Goormastic, M., Corn- hill, J.F., and Chisolm, G.M. 1995. Restenosis after experimental angioplasty: intimal, medial, and adventitial changes associated with constrictive remodeling. Circ. Res. 76: 996-1002. PMID: 7758171.
105. Lamalice, L., Le Boeuf, F., and Huot, J. 2007. Endothelial cell migration during angiogenesis. Circ. Res. 100(6): 782-794. doi:10.1161/01.RES. 0000259593.07661.1e. PMID:17395884.
106. Lansink, M., Koolwijk, P., van Hinsbergh, V., and Kooistra, T. 1998. Effect of steroid hormones and retinoids on the formation of capillary-like tubular structures of human microvascular endothelial cells in fibrin matrices is related to urokinase expression. Blood, 92: 927-938. PMID:9680361.
107. Lansky, A.J., Mintz, G.S., Popma, J.J., Pichard, A.D., Kent, K.M., Satler, L.F., et al. 1998. Remodeling after directional coronary atherectomy (with and without adjunct percutaneous translum- inal coronary angioplasty): a serial angiographic and intravascu- lar ultrasound analysis from the Optimal Atherectomy Restenosis Study. J. Am. Coll. Cardiol. 32: 329-337. doi:10. 1016/S0735-1097(98)00245-9. PMID:9708457.
108. Levine, B., Kalman, J., Mayer, L., Fillit, H.M., and Packer, M. 1990. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323: 236-241. PMID:2195340.
109. Li, H., Liang, J., Castrillon, D.H., DePinho, R.A., Olson, E.N., and Liu, Z.P. 2007. FoxO4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metal- loproteinase 9 gene transcription. Mol. Cell. Biol. 27: 2676-2686. doi:10.1128/MCB.01748-06. PMID:17242183.
110. Lijnen, H.R., Van Hoef, B., Nelles, L., and Collen, D. 1990. Plasminogen activation with single-chain urokinase- type plas- minogen activator (scu-PA): studies with active site mutagen- ized plasminogen (Ser740→Ala) and plasmin- resistant scu-PA (Lys158→Glu). J. Biol. Chem. 265: 5232-5236. PMID:1969415.
111. Lindner, V., and Reidy, M.A. 1993. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and en- dothelium in injured rat arteries: an en face study. Circ. Res. 73: 589-595. PMID:8348698.
112. Lu, H., Mabilat, C., Yeh, P., Guitton, J.D., Li, H., Pouchelet, M., et al. 1996. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells. FEBS Lett. 380: 21-24. doi:10.1016/0014-5793(95)01540-X. PMID: 8603739.
113. Lupu, F., Heim, D.A., Bachmann, F., Hurni, M., Kakkar, V.V., and Kruithof, E.K. 1995. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 15: 1444-1455. PMID:7670960.
114. MacLeod, D.C., Strauss, B.H., de Jong, M., Escaned, J., Umans, V.A., van Suylen, R.J., et al. 1994. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J. Am. Coll. Cardiol. 23: 59-65. PMID:8277096.
115. Mallawaarachchi, C.M., Weissberg, P.L., and Siow, R.C. 2006. Antagonism of platelet-derived growth factor by perivascular gene transfer attenuates adventitial cell migration after vascular injury: new tricks for old dogs? FASEB J. 20: 1686-1688. doi:10. 1096/fj.05-5435fje. PMID:16790526.
116. Mandriota, S.J., Seghezzi, G., Vassalli, J.D., Ferrara, N., Wasi, S., Mazzieri, R., et al. 1995. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J. Biol. Chem. 270(17): 9709-9716. doi:10.1074/jbc.270. 17.9709. PMID:7730348.
117. Mawatari, M., Okamura, K., Matsuda, T., Hamanaka, R., Mizogu- chi, H., Higashio, K., et al. 1991. Tumor necrosis factor and epidermal growth factor modulate migration of human micro- vascular endothelial cells and production of tissue-type plasmi- nogen activator and its inhibitor. Exp. Cell Res. 192: 574-580. doi:10.1016/0014-4827(91)90078-9. PMID:1899074.
118. May, A.E., Kanse, S.M., Lund, L.R., Gisler, R.H., Imhof, B.A., and Preissner, K.T. 1998. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J. Exp. Med. 188: 1029-1037. doi:10.1084/jem.188.6.1029. PMID:9743521. Mazar, A.P., Henkin, J., and Goldfarb, R.H. 1999. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis, 3: 15-32. doi:10.1023/A:1009095825561. PMID:14517441.
119. Menshikov, M., Elizarova, E., Plakida, K., Timofeeva, A., Khaspe- kov, G., Beabealashvilli, R., et al. 2002. Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem. J. 367: 833-839. doi:10.1042/BJ20020663. PMID:12117412.
120. Menshikov, M., Plekhanova, O., Cai, H., Chalupsky, K., Parfyo- nova, Y., Bashtrikov, P., et al. 2006a. Urokinase plasminogen activator stimulates vascular smooth muscle cell proliferation via redox -dependent pathways. Arterioscler. Thromb. Vasc. Biol. 26: 801-807. doi:10.1161/01.ATV. 0000207277.27432.15. PMID:16456094.
121. Menshikov, M., Torosyan, N., Elizarova, E., Plakida, K., Vorotni- kov, A., Parfyonova, Y., et al. 2006b. Urokinase induces matrix metalloproteinase-9/ gelatinase B expression in THP-1 mono- cytes via ERK1/2 and cytosolic phospholipase A2 activation and eicosanoid production. J. Vasc. Res. 43: 482-490. doi:10.1159/000095248. PMID:16926552.
122. Miano, J.M., Vlasic, N., Tota, R.R., and Stemerman, M.B. 1993. Localization of Fos and Jun proteins in rat aortic smooth muscle cells after vascular injury. Am. J. Pathol. 142: 715-724. PMID:8456935.
123. Mimuro, J., Kaneko, M., Murakami, T., Matsuda, M., and Sakata, Y. 1992. Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1. Biochim. Biophys. Acta, 1160: 325-334. PMID:1477106.
124. Mintz, G.S., Popma, J.J., Pichard, A.D., Kent, K.M., Salter, L.F., Chuang, Y.C., et al. 1996a. Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization. J. Am.
125. Mintz, G.S., Popma, J.J., Pichard, A.D., Kent, K.M., Satler, L.F., Wong, C., et al. 1996b. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation, 94: 35-43. PMID:8964115.
126. Monier, S., Parton, R.G., Vogel, F., Behlke, J., Henske, A., and Kurzchalia, T.V. 1995. VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. Mol. Biol. Cell, 6: 911-927. PMID:7579702.
127. Mori, E., Komori, K., Yamaoka, T., Tanii, M., Kataoka, C., Take- shita, A., et al. 2002. Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation, 105: 2905-2910. doi:10.1161/01.CIR.0000018603.67989.71. PMID:12070121.
128. Morimoto, K., Mishima, H., Nishida, T., and Otori, T. 1993. Role of urokinase type plasminogen activator (u-PA) in corneal epithelial migration. Thromb. Haemost. 69: 387-391. PMID:8497852.
129. Mukhina, S., Stepanova, V., Traktouev, D., Poliakov, A., Beabea- lashvilly, R., Gursky, Y., et al. 2000. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain: characterization of interactions and contribution to chemo- taxis. J. Biol. Chem. 275: 16450-16458. doi:10.1074/jbc. M909080199. PMID:10749881.
130. Mulvany, M.J., Baumbach, G.L., Aalkjaer, C., Heagerty, A.M., Korsgaard, N., Schiffrin, E.L., and Heistad, D.D. 1996. Vascular remodeling. Hypertension, 28: 505-506. PMID:8794840.
131. Murayama, H., Takahashi, M., Takamoto, M., Shiba, Y., Ise, H., Koyama, J., et al. 2008. Deficiency of tumour necrosis factor-alpha and interferon- gamma in bone marrow cells synergistically inhibits neointimal formation following vascular injury. Cardiovasc. Res. 80(2): 175-180. doi:10.1093/cvr/cvn250. PMID:18791204.
132. Nagler, A., Miao, H.Q., Aingorn, H., Pines, M., Genina, O., and Vlodavsky, I. 1997. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler. Thromb. Vasc. Biol. 17: 194-202. PMID:9012656.
133. Nakano, H., Nakajima, A., Sakon-Komazawa, S., Piao, J.H., Xue, X., and Okumura, K. 2006. Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ. 13:730-737. doi:10.1038/sj.cdd.4401830. PMID:16341124.
134. Nakata, S., Ito, K., Fujimori, M., Shingu, K., Kajikawa, S., Adachi, W., et al. 1998. Involvement of vascular endothelial growth factor and urokinase- type plasminogen activator receptor in microvessel invasion in human colorectal cancers. Int. J. Cancer, 79: 179-186. doi:10.1002/(SICI)1097- 0215(19980417)79:2〈179::AID- IJC14〉3.0.CO;2-5. PMID:9583734.
135. Naldini, L., Tamagnone, L., Vigna, E., Sachs, M., Hartmann, G., Birchmeier, W., et al. 1992. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 11: 4825-4833. PMID:1334458.
136. Nguyen, D.H., Hussaini, I.M., and Gonias, S.L. 1998. Binding of urokinase- type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J. Biol. Chem. 273: 8502-8507. doi:10.1074/jbc.273.14. 8502. PMID:9525964.
137. Nicholl, S.M., Roztocil, E., and Davies, M.G. 2006. Plasminogen activator system and vascular disease. Curr. Vasc. Pharmacol. 4: 101-116. doi:10.2174/157016106776359880. PMID:16611153.
138. Nikol, S., Huehns, T.Y., and Hofling, B. 1996. Molecular biology and post-angioplasty restenosis. Atherosclerosis, 123: 17-31. doi:10.1016/0021-9150(96)05807-8. PMID:8782834.
139. Nishikawa, T., and Araki, E. 2007. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid. Redox Signal. 9: 343-353. doi:10.1089/ars. 2006.1458. PMID:17184177.
140. Nunes, G.L., Robinson, K., Kalynych, A., King, S.B., III, Sgoutas, D.S., and Berk, B.C. 1997. Vitamins C and E inhibit O2- production in the pig coronary artery. Circulation, 96: 3593-3601. PMID:9396460.
141. Nykjaer, A., Conese, M., Christensen, E.I., Olson, D., Cremona, O., Gliemann, J., and Blasi, F. 1997. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 16: 2610-2620. doi:10.1093/emboj/16.10.2610. PMID:9184208.
142. Odekon, L.E., Sato, Y., and Rifkin, D.B. 1992. Urokinase- type plasminogen activator mediates basic fibroblast growth factor- induced bovine endothelial cell migration independent of its proteolytic activity. J. Cell. Physiol. 150: 258-263. doi:10.1002/jcp. 1041500206. PMID:1734031.
143. Okada, S.S., Tomaszewski, J.E., and Barnathan, E.S. 1995. Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro. Exp. Cell Res. 217: 180-187. doi:10.1006/excr.1995.1077. PMID:7867716.
144. Okada, S.S., Grobmyer, S.R., and Barnathan, E.S. 1996. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. Arterioscler. Thromb. Vasc. Biol. 16: 1269-1276. PMID:8857924.
145. Okamoto, E., Couse, T., De Leon, H., Vinten- Johansen, J., Goodman, R.B., Scott, N.A., and Wilcox, J.N. 2001. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation, 104: 2228-2235. doi:10.1161/hc4301. 097195. PMID:11684636.
146. Okura, H., Shimodozono, S., Hayase, M., Bonneau, H.N., Yock, P.G., and Fitzgerald, P.J. 2002. Impact of deep vessel wall injury and vessel stretching on subsequent arterial remodeling after balloon angioplasty: a serial intravascular ultrasound study. Am. Heart J. 144: 323-328. doi:10.1067/mhj.2002.122282. PMID:12177652.
147. Ono, H., Ichiki, T., Fukuyama, K., Iino, N., Masuda, S., Egashira, K., and Takeshita, A. 2004. cAMP-response element-binding protein mediates tumor necrosis factor-alpha-induced vascular smooth muscle cell migration. Arterioscler. Thromb. Vasc. Biol. 24: 1634-1639. doi:10.1161/01.ATV. 0000138052.86051.0d. PMID:15242860.
148. Ossowski, L. 1992. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res. 52: 6754-6760. PMID:1333882.
149. Ossowski, L., and Aguirre-Ghiso, J.A. 2000. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 12: 613-620. doi:10.1016/S0955-0674(00) 00140-X. PMID:10978898.
150. Ossowski, L., Russo- Payne, H., and Wilson, E.L. 1991. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res. 51: 274-281. PMID:1988089.
151. Ossowski, L., Aguirre, G.J., Liu, D., Yu, W., and Kovalski, K. 1999. The role of plasminogen activator receptor in cancer invasion and dormancy. Medicina (B. Aires), 59: 547-552. PMID:10684157.
152. Overall, C.M., and Lopez-Otin, C. 2002. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer, 2: 657-672. doi:10.1038/nrc884. PMID:12209155.
153. Padro, T., Emeis, J.J., Steins, M., Schmid, K.W., and Kienast, J. 1995. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler. Thromb. Vasc. Biol. 15: 893-902. PMID:7600121.
154. Pakala, R., Willerson, J.T., and Benedict, C.R. 1997. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation, 96: 2280-2286. PMID:9337201.
155. Parfyonova, Y.V., Plekhanova, O.S., and Tkachuk, V.A. 2002. Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Mosc.), 67: 119-134. doi:10.1023/A:1013964517211. PMID:11841347.
156. Parfyonova, Y., Plekhanova, O., Solomatina, M., Naumov, V., Bo- bik, A., Berk, B., and Tkachuk, V. 2004. Contrasting effects of urokinase and tissue-type plasminogen activators on neointima formation and vessel remodelling after arterial injury. J. Vasc. Res. 41: 268-276. doi:10.1159/000078825. PMID:15192267.
157. Pearson, D., Altus, M.S., Horiuchi, A., and Nagamine, Y. 1987. Dexamethasone coordinately inhibits plasminogen activator gene expression and enzyme activity in porcine kidney cells. Biochem. Biophys. Res. Commun. 143: 329-336. doi:10.1016/ 0006-291X(87)90669-3. PMID:3827925.
158. Pepper, M.S., Sappino, A.P., Stocklin, R., Montesano, R., Orci, L., and Vassalli, J.D. 1993. Upregulation of urokinase receptor expression on migrating endothelial cells. J. Cell Biol. 122: 673-684. doi:10.1083/jcb.122.3.673. PMID:8393013.
159. Plekhanova, O.S., Parfyonova, Y.V., Bibilashvily, R.S., Stepanova, V.V., Erne, P., Bobik, A., and Tkachuk, V.A. 2000. Urokinase plasminogen activator enhances neointima growth and reduces lumen size in injured carotid arteries. J. Hypertens. 18: 1065-1069. doi:10.1097/00004872-200018080-00011. PMID:10953998.
160. Plekhanova, O., Parfyonova, Y., Bibilashvily, R., Domogatskii, S., Stepanova, V., Gulba, D.C., et al. 2001. Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms. Atherosclerosis, 159:297-306. doi:10.1016/S0021-9150(01)00511-1. PMID:11730809.
161. Plekhanova, O.S., Solomatina, M.A., Men'shikov, M.I., Bashtry- kov, P.P., Korshunov, V.A., Berk, B.S., et al. 2006a. Plasmino- gen activators and matrix metalloproteinases during arterial remodeling [in Russian]. Kardiologiia, 46: 47-56. PMID:17047623.
162. Plekhanova, O.S., Stepanova, V.V., Ratner, E.I., Bobik, A., Tka- chuk, V.A., and Parfyonova, Y.V. 2006b. Urokinase plasmino- gen activator in injured adventitia increases the number of myofibroblasts and augments early proliferation. J. Vasc. Res. 43: 437-446. doi:10.1159/000094906. PMID:16899994.
163. Plekhanova, O., Berk, B.C., Bashtrykov, P., Brooks, A., Tkachuk, V., and Parfyonova, Y. 2008. Oligonucleotide microarrays reveal regulated genes related to inward arterial remodeling induced by urokinase plasminogen activator. J. Vasc. Res. 46:177-187. doi:10.1159/000156703. PMID:18812699.
164. Plouet, J., Moro, F., Bertagnolli, S., Coldeboeuf, N., Mazarguil, H., Clamens, S., and Bayard, F. 1997. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J. Biol. Chem. 272: 13390-13396. doi:10.1074/jbc.272. 20.13390. PMID: 9148962.
165. Pluskota, E., Soloviev, D.A., and Plow, E.F. 2003. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood, 101: 1582-1590. doi:10.1182/blood-2002-06-1842. PMID:12393547.
166. Poliakov, A.A., Mukhina, S.A., Traktouev, D.O., Bibilashvily, R.S., Gursky, Y.G., Minashkin, M.M., et al. 1999. Chemotactic effect of urokinase plasminogen activator: a major role for mechanisms independent of its proteolytic or growth factor domains. J. Recept. Signal Transduct. Res. 19: 939-951. doi:10.3109/ 10799899909038433. PMID:10533982.
167. Poliakov, A., Tkachuk, V., Ovchinnikova, T., Potapenko, N., Ba- gryantsev, S., and Stepanova, V. 2001. Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation. Biochem. J. 355: 639-645. PMID:11311125.
168. Pollman, M.J., Hall, J.L., and Gibbons, G.H. 1999. Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury: influence of redox state and cell phenotype. Circ. Res. 84: 113-121. PMID:9915780.
169. Post, M.J., Borst, C., and Kuntz, R.E. 1994. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty: a study in the normal rabbit and the hypercholesterolemic Yucatan micropig. Circulation, 89: 2816-2821. PMID:8205696.
170. Pulukuri, S.M., and Rao, J.S. 2007. Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res. 67(14): 6637-6646. doi:10.1158/0008-5472.CAN-07-0751. PMID:17638874.
171. Rabbani, S.A., Desjardins, J., Bell, A.W., Banville, D., Mazar, A., Henkin, J., and Goltzman, D. 1990. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem. Biophys. Res. Commun. 173: 1058-1064. doi:10.1016/S0006-291X(05)80893-9. PMID:2125213.
172. Rabbani, S.A., Mazar, A.P., Bernier, S.M., Haq, M., Bolivar, I., Henkin, J., and Goltzman, D. 1992. Structural requirements for the growth factor activity of the amino- terminal domain of urokinase. J. Biol. Chem. 267: 14151-14156. PMID:1321137.
173. Raghunath, P.N., Tomaszewski, J.E., Brady, S.T., Caron, R.J., Okada, S.S., and Barnathan, E.S. 1995. Plasminogen activator system in human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15: 1432-1443. PMID:7670959.
174. Raines, E.W. 2004. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 15(4): 237-254. doi:10.1016/j.cytogfr.2004. 03.004. PMID:15207815.
175. Rajagopal, V., and Rockson, S.G. 2003. Coronary restenosis: a review of mechanisms and management. Am. J. Med. 115: 547-553. doi:10.1016/S0002- 9343(03)00477-7. PMID:14599634.
176. Rao, N.K., Shi, G.P., and Chapman, H.A. 1995. Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J. Clin. Invest. 96: 465-474. doi:10.1172/JCI118057. PMID:7615819.
177. Reidy, M.A., Irvin, C., and Lindner, V. 1996. Migration of arterial wall cells: expression of plasminogen activators and inhibitors in injured rat arteries. Circ. Res. 78: 405-414. PMID:8593699.
178. Resnati, M., Guttinger, M., Valcamonica, S., Sidenius, N., Blasi, F., and Fazioli, F. 1996. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15: 1572-1582. PMID:8612581.
179. Ried, S., Jager, C., Jeffers, M., Vande Woude, G.F., Graeff, H., Schmitt, M., and Lengyel, E. 1999. Activation mechanisms of the urokinase- type plasminogen activator promoter by hepato- cyte growth factor/scatter factor. J. Biol. Chem. 274: 16377-16386. doi:10.1074/jbc.274.23.16377. PMID:10347197.
180. Romer, J., Lund, L.R., Eriksen, J., Ralfkiaer, E., Zeheb, R., Gelehr- ter, T.D., et al. 1991. Differential expression of urokinase- type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J. Invest. Dermatol. 97: 803-811. doi:10.1111/1523-1747.ep12486833. PMID:1919045.
181. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362: 801-809. doi:10.1038/362801a0. PMID:8479518.
182. Sakata, N., Kawamura, K., and Takebayashi, S. 1990. Effects of collagen matrix on proliferation and differentiation of vascular smooth muscle cells in vitro. Exp. Mol. Pathol. 52: 179-191. doi:10.1016/0014-4800(90)90003-V. PMID:2332035.
183. Saksela, O., and Rifkin, D.B. 1990. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J. Cell Biol. 110: 767-775. doi:10.1083/jcb.110.3.767. PMID: 2137829.
184. Sangiorgi, G., Taylor, A.J., Farb, A., Carter, A.J., Edwards, W.D., Holmes, D.R., et al. 1999. Histopathology of postpercutaneous transluminal coronary angioplasty remodeling in human coronary arteries. Am. Heart J. 138: 681-687. doi:10.1016/S0002- 8703(99)70183-3. PMID:10502214.
185. Schafer, K., Konstantinides, S., Riedel, C., Thinnes, T., Muller, K., Dellas, C., et al. 2002. Different mechanisms of increased lumi- nal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator. Circulation, 106: 1847-1852. doi:10.1161/01.CIR. 0000031162.80988.2B. PMID: 12356640.
186. Schneiderman, J., Bordin, G.M., Engelberg, I., Adar, R., Seiffert, D., Thinnes, T., et al. 1995. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall: a possible mechanism for aneurysm expansion. J. Clin. Invest. 96: 639-645. doi:10.1172/JCI118079. PMID:7615837.
187. Schober, A., and Zernecke, A. 2007. Chemokines in vascular remodeling. Thromb. Haemost. 97(5): 730-737. PMID:17479183.
188. Schonbeck, U., Mach, F., and Libby, P. 1998. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J. Immunol. 161: 3340-3346. PMID:9759850.
189. Schwartz, R.S., and Henry, T.D. 2002. Pathophysiology of coronary artery restenosis. Rev. Cardiovasc. Med. 3(Suppl 5): S4-S9. PMID:12478229.
190. Schwartz, R.S., and Holmes, D.R., Jr. 2001. Vascular disease and injury: preclinical research. Chapter 2. Edited by Simon Daniel, Campbell Rogers. pp. 19-43.
191. Scott, N.A., Cipolla, G.D., Ross, C.E., Dunn, B., Martin, F.H., Simonet, L., and Wilcox, J.N. 1996. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation, 93:2178-2187. PMID:8925587.
192. Seki, N., Bujo, H., Jiang, M., Shibasaki, M., Takahashi, K., Hashimoto, N., and Saito, Y. 2005. A potent activator of PPARalpha and gamma reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits. Atherosclerosis, 178: 1-7. doi:10.1016/j.atherosclerosis.2004.08.015. PMID:15585194.
193. Selzman, C.H., Meldrum, D.R., Cain, B.S., Meng, X., Shames, B.D., Ao, L., and Harken, A.H. 1998. Interleukin-10 inhibits postinjury tumor necrosis factor-mediated human vascular smooth muscle proliferation. J. Surg. Res. 80: 352-356. doi:10.1006/jsre.1998.5486. PMID:9878337.
194. Shah, P.K. 2003. Inflammation, neointimal hyperplasia, and reste- nosis: as the leukocytes roll, the arteries thicken. Circulation, 107: 2175-2177. doi:10.1161/01.CIR.0000069943.41206.BD. PMID:12732592.
195. Shetty, S., Kumar, A., Johnson, A., Pueblitz, S., and Idell, S. 1995. Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis. Am. J. Physiol. 268: L972-L982. PMID:7611439.
196. Shi, Y., O'Brien, J.E., Fard, A., Mannion, J.D., Wang, D., and Za- lewski, A. 1996a. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation, 94: 1655-1664. PMID:8840858.
197. Shi, Y., Pieniek, M., Fard, A., O'Brien, J., Mannion, J.D., and Za- lewski, A. 1996b. Adventitial remodeling after coronary arterial injury. Circulation, 93: 340-348. PMID:8548908.
198. Sieuwerts, A.M., Klijn, J.G., Henzen-Logmans, S.C., and Foekens, J.A. 1999. Cytokine- regulated urokinase- type -plasminogen -activator (uPA) production by human breast fibroblasts in vitro. Breast Cancer Res. Treat. 55: 9-20. doi:10.1023/A:1006190729866. PMID:10472775.
199. Singh, I., Burnand, K.G., Collins, M., Luttun, A., Collen, D., Boel- houwer, B., and Smith, A. 2003. Failure of thrombus to resolve in urokinase- type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation, 107: 869-875. doi:10.1161/01.CIR. 0000050149.22928.39. PMID: 12591758.
200. Sitrin, R.G., Pan, P.M., Harper, H.A., Todd, R.F., III, Harsh, D.M., and Blackwood, R.A. 2000. Clustering of urokinase receptors (uPAR; CD87) induces proinflammatory signaling in human polymorphonuclear neutrophils. J. Immunol. 165: 3341-3349. PMID:10975852.
201. Sitrin, R.G., Pan, P.M., Blackwood, R.A., Huang, J., and Petty, H.R. 2001. Cutting edge: evidence for a signaling partnership between urokinase receptors (CD87) and L-selectin (CD62L) in human polymorphonuclear neutrophils. J. Immunol. 166: 4822-4825. PMID:11290756.
202. Siwik, D.A., and Colucci, W.S. 2004. Regulation of matrix metal- loproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail. Rev. 9: 43-51. doi:10.1023/ B:HREV.0000011393. 40674.13. PMID:14739767.
203. Smith, J.D., Bryant, S.R., Couper, L.L., Vary, C.P., Gotwals, P.J., Koteliansky, V.E., and Lindner, V. 1999. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ. Res. 84: 1212-1222. PMID:10347096.
204. Soda, T., Suzuki, H., Iso, Y., Kusuyama, T., Omori, Y., Sato, T., et al. 2007. Bone marrow cells contribute to neointimal formation after stent implantation in swine. Int. J. Cardiol. 121: 44-52. doi:10.1016/j.ijcard. 2006.10.031. PMID:17254651.
205. Stepanova, V., Bobik, A., Bibilashvily, R., Belogurov, A., Ry- balkin, I., Domogatsky, S., et al. 1997. Urokinase plasminogen activator induces smooth muscle cell migration: key role of growth factor-like domain. FEBS Lett. 414: 471-474. doi:10. 1016/S0014-5793(97)00993-9. PMID:9315743.
206. Stepanova, V., Mukhina, S., Kohler, E., Resink, T.J., Erne, P., and Tkachuk, V.A. 1999. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis- dependent mechanisms. Mol. Cell. Biochem. 195: 199-206. doi:10.1023/ A:1006936623106. PMID:10395084.
207. Stepanova, V., Lebedeva, T., Kuo, A., Yarovoi, S., Tkachuk, S., Zaitsev, S., et al. 2008a. Nuclear translocation of urokinase- type plasminogen activator. Blood, 112: 100-110. doi:10.1182/blood-2007-07-104455. PMID:18337556.
208. Stepanova, V.V., Beloglazova, I.B., Gursky, Y.G., Bibilashvily, R.S., Parfyonova, Y.V., and Tkachuk, V.A. 2008b. Interaction between kringle and growth-factor-like domains in the urokinase molecule: possible role in stimulation of chemotaxis. Biochemistry (Mosc.), 73: 252-260. PMID:18393759.
209. Stoppelli, M.P., Verde, P., Grimaldi, G., Locatelli, E.K., and Blasi, F. 1986. Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate. J. Cell Biol. 102: 1235-1241. doi:10.1083/jcb.102.4. 1235. PMID:3958045.
210. Strauss, B.H., Lau, H.K., Bowman, K.A., Sparkes, J., Chisholm, R.J., Garvey, M.B., et al. 1999. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation, 100: 1616-1622. PMID:10517732.
211. Stump, D.C., Lijnen, H.R., and Collen, D. 1986. Purification and characterization of a novel low molecular weight form of single-chain urokinase- type plasminogen activator. J. Biol. Chem. 261: 17120-17126. PMID:3097021.
212. Suematsu, M., Suzuki, H., Delano, F.A., and Schmid- Schonbein, G.W. 2002. The inflammatory aspect of the microcirculation in hypertension: oxidative stress, leukocytes/endothelial interaction, apoptosis. Microcirculation, 9: 259-276. doi:10.1038/sj.mn.7800141. PMID:12152103.
213. Tanaka, K., Sata, M., Hirata, Y., and Nagai, R. 2003. Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ. Res. 93: 783-790. doi:10.1161/01.RES.0000096651. 13001.B4. PMID:14500338.
214. Tanaka, K., Sata, M., Natori, T., Kim-Kaneyama, J.R., Nose, K., Shi- banuma, M., et al. 2008. Circulating progenitor cells contribute to neointimal formation in nonirradiated chimeric mice. FASEB J. 22: 428-436. doi:10.1096/fj.06-6884com. PMID:17848623.
215. Tang, H., Kerins, D.M., Hao, Q., Inagami, T., and Vaughan, D.E. 1998. The urokinase- type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen- activated protein kinase in cultured endothelial cells. J. Biol. Chem. 273: 18268-18272. doi:10. 1074/jbc.273.29.18268. PMID:9660790.
216. Tkachuk, V., Stepanova, V., Little, P.J., and Bobik, A. 1996. Regulation and role of urokinase plasminogen activator in vascular remodelling. Clin. Exp. Pharmacolysiol. 23: 759-765. doi:10.1111/j.1440-1681.1996.tb01177.x. PMID:8911711.
217. Todd, R.F., III, and Petty, H.R. 1997. Beta 2 (CD11/CD18) integ- rins can serve as signaling partners for other leukocyte receptors. J. Lab. Clin. Med. 129: 492-498. doi:10.1016/S0022- 2143(97)90003-2. PMID:9142045.
218. Traktuev, D.O., Tsokolaeva, Z.I., Shevelev, A.A., Talitskiy, K.A., Stepanova, V.V., Johnstone, B.H., et al. 2007. Urokinase gene transfer augments angiogenesis in ischemic skeletal and myocardial muscle. Mol. Ther. 15: 1939-1946. doi:10.1038/sj.mt. 6300262. PMID:17653104.
219. Ugwu, F., Van Hoef, B., Bini, A., Collen, D., and Lijnen, H.R. 1998. Proteolytic cleavage of urokinase- type plasminogen activator by stromelysin-1 (MMP-3). Biochemistry, 37: 7231-7236. doi:10.1021/bi9728708. PMID:9585535.
220. Ungvari, Z., Wolin, M.S., and Csiszar, A. 2006. Mechanosensitive production of reactive oxygen species in endothelial and smooth muscle cells: role in microvascular remodeling? Antioxid. Redox Signal. 8: 1121-1129. doi:10.1089/ars.2006.8.1121. PMID:16910760.
221. van Hinsbergh, V.W., Engelse, M.A., and Quax, P.H. 2006. Peri- cellular proteases in angiogenesis and vasculogenesis. Arterios-cler. Thromb. Vasc. Biol. 26(4): 716-728. doi:10.1161/01.ATV. 0000209518.58252.17. PMID:16469948.
222. van Weel, V., van Tongeren, R.B., van Hinsbergh, V.W., van Bockel, J.H., and Quax, P.H. 2008. Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation. Ann. Vasc. Surg. 22: 582-597. doi:10.1016/j.avsg.2008.02. 017. PMID:18504100.
223. Vassalli, J.D., Baccino, D., and Belin, D. 1985. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100: 86-92. doi:10.1083/jcb.100.1.86. PMID:3880760.
224. Voisard, R., Voglic, S., Baur, R., Susa, M., Koenig, W., and Hom- bach, V. 2001. Leukocyte attack in a 3D human coronary in- vitro model. Coron. Artery Dis. 12: 401-411. doi:10.1097/ 00019501-200108000-00010. PMID:11491206.
225. Waller, B.F., Pinkerton, C.A., Orr, C.M., Slack, J.D., VanTassel, J.W., and Peters, T. 1991. Restenosis 1 to 24 months after clinically successful coronary balloon angioplasty: a necropsy study of 20 patients. J. Am. Coll. Cardiol. 17: 58B-70B. PMID: 2016484.
226. Waltz, D.A., Sailor, L.Z., and Chapman, H.A. 1993. Cytokines induce urokinase- dependent adhesion of human myeloid cells: a regulatory role for plasminogen activator inhibitors. J. Clin. Invest. 91: 1541-1552. doi:10.1172/JCI116360. PMID: 8386190.
227. Wang, N., Planus, E., Pouchelet, M., Fredberg, J.J., and Barlovatz- Meimon, G. 1995. Urokinase receptor mediates mechanical force transfer across the cell surface. Am. J. Physiol. 268: C1062-C1066. PMID:7733228.
228. Wei, Y., Waltz, D.A., Rao, N., Drummond, R.J., Rosenberg, S., and Chapman, H.A. 1994. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269:32380-32388. PMID:7528215.
229. Wei, Y., Yang, X., Liu, Q., Wilkins, J.A., and Chapman, H.A. 1999. A role for caveolin and the urokinase receptor in integ- rin- mediated adhesion and signaling. J. Cell Biol. 144: 1285-1294. doi:10.1083/jcb.144.6.1285. PMID:10087270.
230. Weintraub, W.S. 2007. The pathophysiology and burden of restenosis. Am. J. Cardiol. 100: 3K-9K. doi:10.1016/j.amjcard.2007.06.002. PMID:17719351.
231. Wilcox, J.N., and Scott, N.A. 1996. Potential role of the adventitia in arteritis and atherosclerosis. Int. J. Cardiol. 54(Suppl): S21- S35. doi:10.1016/0167-5273(95)02516-2. PMID:9119525.
232. Xue, W., Mizukami, I., Todd, R.F., III, and Petty, H.R. 1997. Urokinase- type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 57: 1682-1689. PMID:9135008.
233. Yamamoto, M., Yamamoto, K., and Noumura, T. 1993. Type I collagen promotes modulation of cultured rabbit arterial smooth muscle cells from a contractile to a synthetic phenotype. Exp. Cell Res. 204: 121-129. doi:10.1006/excr.1993.1016. PMID: 8416790.
234. Yu, W., Kim, J., and Ossowski, L. 1997. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J. Cell Biol. 137: 767-777. doi:10.1083/jcb.137.3. 767. PMID:9151680.
235. Zernecke, A., Schober, A., Bot, I., von Hundelshausen, P., Liehn, E.A., Mopps, B., et al. 2005. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ. Res. 96: 784-791. doi:10.1161/01.RES.0000162100.52009.38. PMID:15761195.